How Many CAR-Ts Do We Need to Test Drive? Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology. https://t.co/mxEjUeiTnj https://t.co/m60ZWKp5b6

Looking for practical clinical insights you can apply today? RheumNow Therapeutic Updates bring together expert faculty perspectives, emerging data, treatment trends, patient management strategies, and real-world clinical experience across rheumatology. Explore the latest https://t.co/1rYrCG6EPJ

Genicular artery embolization (GAE) in knee OA? Multiple open label studies & metanalyses suggest a clear pain benefit; BUT 3 sham-controlled RCTs have not demonstrated a statistically significant benefit over placebo. GAE is not addressed by ACR or EULAR guidelines. https://t.co/4JPm7gzCue

From Cytokine Endotypes to Clinical Reality in Still’s Disease Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy. https://t.co/FrghBJdlXj https://t.co/CbHYDKbnK9

Increased VTE Risk with Baricitinib The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026 (LB0009). This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — https://t.co/5cQ829x77u

The congress may be over, but the learning continues. RheumNow's EULAR 2026 coverage hub brings together expert reporting, clinical commentary, daily recaps, podcasts, and key takeaways from the meeting's most important presentations. Catch up on: ✔️ Rheumatoid Arthritis ✔️ https://t.co/TU6zIOvIy3

Induction of Cure in Early Arthritis treated early DMARD-naïve Undiff. Arthritis (≥2 joints) w/ NSAIDs (29), MTX 15-25/wk (28), or baricitinib 4 mg/d (28) x 3 mos. Entry DAS ~ 2.4 w/ 2-3 SJC, <17%CCP+. @3 mos Bari > NSAID (DAS−0.52;p=0.01) = MTX (−0.39, p=0.09).@1yr MTX DAS https://t.co/1kKjginhKM

20% sample of elder RA Medicare pts (2009-2022) on TNFi who either stopped or tapered TNFi found 38% sustained de-escalation, while 62% re-escalated within a medianof 164. Re-escalation was more likely in Blacks, Hispanic/other, with a lower comorbidity burden. https://t.co/rEB3VdOii2

US telehealth utilization rose 10.1% in 1st quarter of 2026 (5% to 5.51% medical claims). Most use in mental health conditions (52%) w/ joint/soft tissue dz at 3% overall, higher in west & NE states. 57% for outpt visits, only 7.7% for new visits. 35% for psychotherapy services. https://t.co/L8c7p3iQPL

From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg

Nature has published that Hyperglycosylation is a metabolic driver of Alzheimer’s Dz (AD) & Glucosamine (GS; taken by ~7% over 70yrs) & GS may increase hyperglycosylation. A retrosp EHR study of AD pts shows glucosamine use assoc w/ accelerated AD progression & worse survival https://t.co/bv6H9h6gAv

Long-term Cancer Risk with Targeted Therapy in SpA Dr. Antoni Chan reports on abstract OP0238 presented at EULAR 2026 in London https://t.co/f67SvKI6Vk https://t.co/fPp2H0aMoK